GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation.

Dachy, François;Furst, Sabine;Calmels, Boris;Pagliardini, Thomas;Devillier, Raynier;et.al.
(2023) Bone Marrow Transplantation — Vol. 58, n° 11, p. 1179-1181 (2023)

Files

DachyFBoneMarrowTransplant2023.pdf
  • Open Access
  • Adobe PDF
  • 583.88 KB
Download

Details

Authors
  • Dachy, Françoisorcid-logoUCLouvain
    Author
  • Furst, Sabine
    Author
  • Calmels, Borisorcid-logo
    Author
  • Pagliardini, Thomas
    Author
  • Devillier, Raynierorcid-logo
    Author
Show more
Abstract
(en) Antithymocyte globulin (ATG) as part of graft-versus-host disease (GVHD) prophylaxis for peripheral blood stem cells (PBSC) transplant significantly reduced the risk of GVHD and thus progressively became a standard, notably for unrelated donor (UD) allogeneic cell transplantation (allo-HCT). More recently, GVHD prophylaxis with post-transplant cyclophosphamide (PT-Cy) was introduced in the setting of haploidentical allo-HCT (haplo-HCT), with low incidence of GVHD despite the HLA donor-recipient disparity. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Dachy, F., Furst, S., Calmels, B., Pagliardini, T., Harbi, S., Bouchacourt, B., Calleja, A., Lemarie, C., Collignon, A., Morel, G., Legrand, F., Bekrieva, E., Granata, A., Weiller, P. J., Chabannon, C., Schiano, J. M., Vey, N., Blaise, D., & Devillier, R. (2023). GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 58(11), 1179-1181. https://doi.org/10.1038/s41409-023-02033-0 (Original work published 2023)